Life Sciences

  • February 11, 2026

    Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now

    An Illinois federal judge on Wednesday tossed out Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfidera, but said the standing issues primarily dooming their complaint can likely be cured if they amend their pleading.

  • February 11, 2026

    NY Judge Rejects Bid To Stop SD Action Against Abortion Ads

    A New York federal judge said Wednesday that she can't block South Dakota officials from pursuing state legal action against an abortion rights group that launched an advertising campaign in South Dakota, saying she doesn't have jurisdiction to halt the proceedings.

  • February 11, 2026

    Supreme Court Sets April Argument For 'Skinny Label' Case

    The U.S. Supreme Court has set an April 29 date for oral arguments in Hikma Pharmaceutical Inc.'s appeal of a decision that revived a patent case over its "skinny label" on a generic heart drug.

  • February 11, 2026

    7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal

    Seventh Circuit judges Wednesday pressed counsel for Teva Pharmaceuticals USA Inc. to address how long a settlement under which Eli Lilly & Co. agreed not to block the approval and marketing of Teva's generic version of its osteoporosis drug Forteo could reasonably remain in effect, given Teva's drug wasn't ready for market until years after the underlying patent dispute.

  • February 11, 2026

    Shkreli Can't Add Wu-Tang Members To Fight With Crypto Co.

    "Pharma Bro" Martin Shkreli can't drag two members of the Wu-Tang Clan hip-hop group into a suit brought by a crypto firm that claims Shkreli improperly retained copies of an album that it bought the rights to, a New York federal judge ruled on Wednesday.

  • February 11, 2026

    Beasley Allen Wants Talc DQ Paused Pending High Court Appeal

    Hundreds of women who claim their ovarian cancer was caused by Johnson & Johnson's talcum powder risk appearing in an upcoming trial without their preferred counsel from the Beasley Allen Law Firm, unless a New Jersey state court stays an order disqualifying the firm, it said.

  • February 11, 2026

    Trans Health And Pediatric Groups Challenge FTC Subpoenas

    A major transgender medical group and a pediatric healthcare organization are seeking to end what they call "unlawful" consumer protection investigations from the Federal Trade Commission that want information pertaining to the medical groups' claims made in their marketing and advertising for gender-affirming care for minors. 

  • February 10, 2026

    Judge Limits Insurers' Exposure in Opioid Coverage Fight

    Insurers garnered several wins Tuesday in a dispute over coverage for thousands of opioid suits against bankrupt pharmaceutical company Endo International, with a Pennsylvania federal court ruling favorably for the carriers on the interpretation of claims-made provisions and the meaning of "damages for bodily injury."

  • February 10, 2026

    GSK, Teva Settle 'Skinny Label' Heart Medication Suit

    GlaxoSmithKline and Teva told a Delaware federal judge that they've settled GSK's decade-long "skinny label" patent fight over heart failure medication and asked the court to end the case.

  • February 10, 2026

    Jury Asked To 'Send A Message' To J&J As Talc Trial Wraps

    Counsel for a woman who died of ovarian cancer asked a Philadelphia jury to "send a message" with its verdict at the closing of the court's second talc mass tort trial against Johnson & Johnson, suggesting they should consider the company's multibillion-dollar net worth when coming up with a punitive damages award.

  • February 10, 2026

    Lutnick Rules Out Creating Value-Based Fees For Patents

    Commerce Secretary Howard Lutnick told a Senate panel Tuesday that the government is not planning to establish new fees for U.S. patents based on their value, saying the idea he was reportedly considering "is not going anywhere."

  • February 10, 2026

    Lipid Testing Patents Recite Laws Of Nature, Judge Says

    A Massachusetts federal judge has dismissed a company's infringement claims against a rival over patents that cover methods of testing for lysosomal storage disorders, ruling that the patents only cited patent-ineligible laws of nature.

  • February 10, 2026

    Apple Again Pushes To Escape Masimo's $634M IP Verdict

    Apple is doubling down on its bid to have U.S. District Judge James V. Selna relieve it from a jury's $634 million infringement verdict in litigation over its Apple Watch, saying Masimo Corp. relied on an improper and "shifting" definition of a dispositive term.

  • February 10, 2026

    Pa. Hospital Settles Ex-Worker's ADA Suit Over CBD Gummy

    UPMC Pinnacle Hospitals has settled a former employee's disability discrimination suit claiming he was unlawfully fired when he tested positive for cannabis because he took cannabidiol gummies used to treat his spinal condition.

  • February 10, 2026

    Judge Questions Timing Of Case Against Harvard Researcher

    A Massachusetts federal judge on Tuesday ordered the U.S. Attorney's Office to turn over materials related to its decision to prosecute a Harvard Medical School researcher and Russian national found with inert frog embryo specimens last year at Logan Airport, calling the timing of the case "a red flag."

  • February 10, 2026

    Astellas Gets $90M From Lupin In Myrbetriq Patent Deal

    Generic-drug maker Lupin Pharmaceuticals has inked a deal to pay $90 million to settle claims that it infringed patents held by rival Astellas Pharma Inc. covering name-brand bladder drug Myrbetriq.

  • February 10, 2026

    Norton Rose Hires Cooley Life Sciences Duo In DC

    Norton Rose Fulbright has hired two life sciences attorneys from Cooley LLP in Washington, D.C., who focus on biotech and pharmaceutical intellectual property matters, in a move the firm said is an investment in IP as a core practice.

  • February 10, 2026

    Whooping Cough-Focused Biotech Wraps $115M Fundraise

    Florida-based biotechnology company ILiAD Biotechnologies Inc. on Tuesday revealed that it wrapped its latest financing round after securing $115 million from investors, which will be used to advance development on a potential whooping cough vaccine.

  • February 09, 2026

    Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages

    Kurin has urged a Delaware federal judge to overturn Magnolia Medical's $1.6 million patent verdict or order a new trial, while Magnolia Medical has asked the court to bar Kurin from selling allegedly infringing "Jet" blood-culture collection products and award it supplemental damages on Kurin's sales, plus ongoing royalties and interest.

  • February 09, 2026

    Defendant Mix-Up Ends Biotech FCA Suit, For Now

    A New York federal court ruled that a relator's False Claims Act suit failed to link claims of improper COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend.

  • February 09, 2026

    Italian Biathlete Lodges Appeal Of Olympic Doping Ban

    Italian biathlete Rebecca Passler, who was booted from the Olympic team last week after a positive doping test, has appealed the decision to the Court of Arbitration for Sport, asserting that the test result arose from a contamination issue.

  • February 09, 2026

    Fed. Circ. Sends Blood Pump Patent Fight Back To Mass.

    The Federal Circuit on Monday reversed a lower court's ruling that Abiomed Inc. hasn't infringed five patents on blood pump systems and methods, while backing the part of the decision that cleared the medical device technology company of allegations it infringed a different patent.

  • February 09, 2026

    Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1

    Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.

  • February 09, 2026

    High Court Asked To Take Up Malpractice Case Against Akin

    A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

Expert Analysis

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.